Tag:

Biomarker

Health

CDC Report: 24-Year Trends in American Nutrition and Health

by Chief Editor
written by Chief Editor

The New Era of Nutritional Intelligence: How Biochemical Data is Reshaping Health

For decades, our understanding of national nutrition was largely built on what people said they ate. While dietary surveys provide valuable insights, they often struggle with the gap between reported intake and actual biological absorption. We are now entering a transformative era where “gold standard” scientific data is moving beyond the kitchen and into the bloodstream.

The upcoming 2026 “National Report on Biochemical Indicators of Diet and Nutrition in the US Population,” scheduled for release by the Centers for Disease Control and Prevention (CDC), represents a massive leap forward. By synthesizing nearly 24 years of data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to August 2023, this report provides a high-resolution snapshot of the nation’s nutritional reality through 131 different biomarkers.

Did you know?
The NHANES survey is considered one of the world’s most durable and comprehensive national nutrition surveillance systems. Unlike many other countries, the US incorporates biological samples—including blood and urine—to validate nutritional status.

From Self-Reporting to Biological Certainty

The future of nutritional science is shifting toward biochemical validation. The 2026 report highlights this by presenting nationally representative measurements for a staggering array of indicators, including water-soluble and fat-soluble vitamins, trace elements, and bioactive compounds.

From Self-Reporting to Biological Certainty
Americans

One of the most significant trends emerging is the focus on complex, multi-indicator markers. Rather than looking at a single nutrient in isolation, researchers are increasingly looking at combined indicators to get a clearer picture of health. For example, the report introduces vitamin B12 status through a combined indicator (cB-12) that incorporates vitamin B-12, methylmalonic acid, and total homocysteine.

The Rise of “Heart-Health” Biomarkers

We are also seeing a deeper dive into lipid profiles and fatty acid health. The inclusion of the omega-3 index—derived from eicosapentaenoic acid and docosahexaenoic acid as a percentage of total fatty acids in red cells—marks a trend toward using specific biomarkers to predict long-term cardiovascular outcomes. This level of detail allows for a much more nuanced understanding of how dietary patterns actually manifest in human biology.

The Supplement Question: A Data-Driven Divide

For years, the impact of dietary supplements on national health has been a subject of intense debate. Are Americans actually benefiting from their daily multivitamins, or is there a significant gap between supplement use and biological sufficiency?

CDC Guide to Healthy Eating and Nutrition Principles

The 2026 report addresses this head-on by presenting concentrations for supplement users and nonusers separately for the first time. This distinction is a game-changer for several reasons:

  • Validation of Claims: It allows researchers to see if supplement use actually correlates with higher biomarker levels.
  • Targeted Guidance: It helps clinicians understand if certain populations are over-relying on supplements to compensate for poor dietary patterns.
  • Policy Development: It provides the data necessary to frame programs that address nutritional gaps more effectively.
Pro Tip for Clinicians:
When interpreting patient health, use national reference intervals as a baseline, but remember that these reports provide descriptive, unadjusted population data. Always correlate biomarker levels with individual medical histories and lifestyle factors.

Predicting Trends: The Power of 24 Years of Data

The true power of the NHANES data lies in its longitudinal depth. With over 2,700 tables and 500 figures, the 2026 report doesn’t just show where we are; it shows where we have been. By analyzing percentile concentration trends over nearly 24 years, scientists can identify whether the nation’s nutritional health is improving, stagnating, or declining.

This “substantial data” approach enables Precision Public Health. Instead of broad, one-size-fits-all nutritional advice, future interventions can be stratified by age, sex, race, and Hispanic origin. We can move toward a model where public health policy is as specific as a personalized nutrition plan.

Key Areas of Future Focus:

  • Trace Element Monitoring: Tracking levels of copper and zinc in the blood to understand mineral deficiencies.
  • Metabolic Markers: Utilizing caffeine and its metabolites to study lifestyle-driven metabolic shifts.
  • Fatty Acid Profiles: Expanding the study of RBC fatty acids and trans-fatty acids to better understand systemic inflammation.

As we look toward the future, the integration of sociodemographic, lifestyle, and biological data will continue to refine our understanding of human health. The 2026 Nutrition Report is not just a collection of numbers; it is a roadmap for the next generation of wellness and disease prevention.

Frequently Asked Questions

What is the NHANES survey?

The National Health and Nutrition Examination Survey (NHANES) is a comprehensive program that combines interviews and physical examinations to assess the health and nutritional status of the US population.

Frequently Asked Questions
American Nutrition Examination

Why are biomarkers important for nutrition?

Biomarkers (found in blood and urine) provide objective evidence of nutrient levels, offering a much more accurate picture of health than dietary surveys alone, which rely on memory and self-reporting.

How many biomarkers are in the 2026 report?

The report presents data for up to 131 nutritional biomarkers, covering a wide range of vitamins, trace elements, and bioactive compounds.

Who can use this report?

The report is designed as a resource for policymakers, clinicians, and researchers to help identify health priorities, develop guidelines, and monitor the effectiveness of health interventions.

Want to stay ahead of the latest health science trends?

Subscribe to our newsletter for deep dives into nutritional research and public health updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Healthy plant-based foods may improve pregnancy cardiometabolic markers

by Chief Editor
written by Chief Editor

Beyond “Plant-Based”: Why Quality is the New Gold Standard for Pregnancy Nutrition

For years, the nutritional conversation around pregnancy has been binary: eat meat or go plant-based. However, emerging data is shifting the narrative. A recent analysis of NHANES (National Health and Nutrition Examination Survey) data suggests that for expectant mothers, what plants you eat are far more important than whether you avoid animal products entirely.

The study, published in Nutrition and Health, reveals a critical nuance: the quality of plant-based foods—specifically those that are nutrient-dense and low in refined sugars—has a more profound impact on cardiometabolic biomarkers than the simple exclusion of meat.

The Quality Gap: Not All Plant-Based Diets Are Equal

When we hear “plant-based,” we often picture kale salads and quinoa. But a “plant-based” diet can technically include white bread, sugary sodas, and highly processed potato chips. This is where the distinction between a Plant-Based Diet Index (PDI) and a healthful Plant-Based Diet Index (hPDI) becomes vital.

The research highlighted that indices emphasizing “Healthy PBF” (Plant-Based Foods)—which exclude added sugars, refined grains, and fruit juices—were most strongly associated with favorable health markers. In contrast, simply eating more plants without focusing on quality didn’t yield the same metabolic rewards.

Did you know? The “Modified Healthy PBF” index used in the study specifically excluded white potatoes and added sugars while including plant oils, showing a stronger link to lower insulin resistance than general plant-based patterns.

Decoding the Biomarkers: What Really Matters During Pregnancy

To understand the future of prenatal health, we have to look at the biomarkers. The study focused on cardiometabolic health, which essentially measures how your body handles energy and fats. Key findings included:

From Instagram — related to Decoding the Biomarkers, Future Trends
  • HOMA-IR and Insulin: Higher scores in healthful plant-based indices were linked to lower insulin levels and lower homeostatic model assessment for insulin resistance (HOMA-IR). This suggests a reduced risk of developing gestational diabetes.
  • HDL-C (The “Good” Cholesterol): Across almost all plant-based indices, there was a positive association with higher HDL-C levels, which helps remove other forms of cholesterol from your bloodstream.
  • TG/HDL-C Ratio: A lower ratio of triglycerides to HDL cholesterol is a strong indicator of better cardiovascular health, and this was consistently seen in women prioritizing high-quality plant foods.

This suggests that the future of pregnancy nutrition isn’t about restriction, but about optimization. By focusing on nutrient-dense plants, women can support their metabolic health without the stress of strictly eliminating animal proteins if they choose not to.

Future Trends: The Rise of Precision Prenatal Nutrition

As we move toward a more data-driven approach to health, we can expect several shifts in how pregnancy nutrition is managed:

Whole food plant-based diet for fertility, pregnancy, and breastfeeding

1. From “General Guidelines” to “Biomarker-Based” Diets

Instead of a one-size-fits-all food pyramid, we are moving toward precision nutrition. Future prenatal care may involve monitoring HOMA-IR and lipid profiles in real-time to adjust dietary intake, ensuring the mother’s metabolic health is optimized for both her and the developing fetus.

2. The End of the “Vegan vs. Omnivore” Debate

The NHANES analysis suggests that the “quality of plant foods may be more crucial than limiting animal foods.” This paves the way for a “Plant-Forward” approach—where the plate is dominated by whole plants, but high-quality animal proteins are viewed as complementary rather than detrimental.

3. Focus on “Ultra-Processed” Plant Foods

The industry is seeing a surge in “vegan” processed foods. However, as the CDC emphasizes, healthy eating means focusing on whole, nutrient-dense foods. The future trend will likely be a crackdown on “healthy-washing,” where plant-based labels hide high levels of sodium and refined carbohydrates.

3. Focus on "Ultra-Processed" Plant Foods
pregnant woman healthy diet
Pro Tip: To build a “Modified Healthy PBF” plate, swap white rice for farro or quinoa, replace fruit juice with whole berries, and use avocado or olive oil instead of processed vegetable oils.

Practical Steps for a Cardiometabolic-Friendly Pregnancy

If you are looking to implement these findings, the goal is to maximize “Healthy PBF” while minimizing refined inputs. Consider these shifts:

  • Prioritize Colors: Incorporate dark leafy greens, orange sweet potatoes, and deep red berries. As noted by the World Health Organization, diversity and balance are the foundations of any healthy diet.
  • Audit Your Grains: Move away from “white” carbohydrates (white bread, white pasta) and toward intact grains like oats, buckwheat, and brown rice.
  • Smart Fats: Focus on seeds, nuts, and plant-based oils that support HDL cholesterol levels.

Frequently Asked Questions

Q: Does this mean I should stop eating meat during pregnancy?
A: Not necessarily. The study suggests that the quality of the plant foods you add to your diet is more impactful for cardiometabolic health than the act of removing animal foods.

Q: What exactly are “unhealthy” plant-based foods?
A: These typically include refined grains (white flour), added sugars (syrups, cane sugar), and highly processed fruit juices.

Q: How does insulin resistance affect pregnancy?
A: High insulin resistance (measured by HOMA-IR) can increase the risk of gestational diabetes and other cardiometabolic complications. A healthful plant-based diet helps keep these levels in check.

What has your experience been with plant-based eating during pregnancy? Do you find it harder to avoid processed “healthy” foods than actual meat? Let us know in the comments below or subscribe to our newsletter for more evidence-based nutrition deep dives!

0 comments
0 FacebookTwitterPinterestEmail
Health

Research links specific diets to reduced biological age

by Chief Editor
written by Chief Editor

Beyond the Calendar: Understanding Biological Age

Most of us view aging as an inevitable march of time—a chronological count of years. However, science is increasingly distinguishing between chronological age and biological age. While your birthday remains the same, your biological age reflects your body’s actual health status and its resilience against the wear and tear of time.

According to recent research from the University of Sydney, biological age is not a fixed destination but a fluid state. By analyzing biomarker profiles—measures of physiological function over time—scientists can now estimate how “old” a person’s body actually is. This shift in perspective suggests that we may have more control over our aging process than previously thought.

Did you know? Biological age is often considered a superior indicator of overall health and potential longevity compared to chronological age because it accounts for individual differences in health and physiological resilience.

Can Diet Rapidly “Reverse” Biological Aging?

The possibility of using nutrition to influence biological age has moved from theory to evidence. A study conducted at the University’s Charles Perkins Centre, published in Aging Cell, explored how specific dietary interventions affect adults aged 65 to 75.

The findings were striking: participants subjected to dietary changes for just four weeks showed a reduction in their biological age based on their biomarker profiles. This suggests that the body’s physiological markers can respond rapidly to nutritional shifts, offering a glimmer of hope for improving health outcomes later in life.

The research integrated data from 20 different biomarkers to calculate these age scores, including critical indicators such as:

  • Blood levels of cholesterol
  • Insulin levels
  • C-reactive protein

The Protein and Fat Lever: What Actually Works?

Not all diets are created equal when it comes to biological aging. The Nutrition for Healthy Living study divided 104 participants into four distinct dietary categories, all maintaining 14 percent of their energy from protein. The groups were split between omnivorous and semi-vegetarian diets, and further divided by fat and carbohydrate levels.

The Protein and Fat Lever: What Actually Works?
Biological Aging

The Winning Profiles

The study found that participants who reduced either dietary fat or animal-based protein showed signs of reduced biological age. Specifically, the omnivorous high-carbohydrate (OHC) group—whose diet consisted of 14 percent protein, 28-29 percent fat, and 53 percent carbohydrates—showed reductions with the highest degree of statistical confidence.

In contrast, the omnivorous high-fat (OHF) group, whose diet most closely mirrored their original baseline eating habits, showed no meaningful change in their biological age profile. This highlights a potential trend: shifting away from high-fat, animal-heavy diets may be a key lever in modulating physiological aging.

Pro Tip: To mirror the findings of the semi-vegetarian groups in the study, try replacing a portion of your animal proteins with plant-based sources. In the study, semi-vegetarian participants derived 70 percent of their protein from plants.

The Future of Longevity: From Data to Disease Prevention

While these short-term results are promising, the scientific community is cautious about claiming a “cure” for aging. The goal is shifting from simply extending the number of years we live to extending our healthspan—the period of life spent in good health.

Associate Professor Alistair Senior from the School of Life and Environmental Sciences and the Charles Perkins Centre emphasizes that we are still in the early stages. “Longer term dietary changes are needed to assess whether dietary changes alter the risk of age-related diseases,” he notes.

The future of this field likely lies in personalized nutrition. By monitoring biomarker profiles, healthcare providers may one day prescribe specific dietary “dosages” of fats and proteins to keep a patient’s biological age lower than their chronological age.

Dr. Caitlin Andrews, who led the research, suggests that while it is too soon to definitively say these changes will extend life, they provide an “early indication of the potential benefits of dietary changes later in life.” Future trends will likely focus on whether these results are sustained over years rather than weeks and if they apply to younger cohorts.

Frequently Asked Questions

Can I actually reverse my biological age?
Preliminary research suggests that dietary interventions, such as reducing animal-based proteins or fats, can reduce biological age markers in a short period. However, long-term sustainability and impact on lifespan are still being studied.

Frequently Asked Questions
University of Sydney

What is the difference between chronological and biological age?
Chronological age is the number of years you have been alive. Biological age is an estimate of your body’s health and physiological function based on biomarkers.

Which diet showed the most promise in the University of Sydney study?
The omnivorous high-carbohydrate (OHC) diet showed the highest statistical confidence in reducing biological age markers among the participants.

How long does it take to see a change in biological markers?
In this specific study, participants showed changes in their biomarker profiles after just four weeks of dietary intervention.

For more insights on how to optimize your health, explore our guide on healthy aging tips or learn more about the latest in aging cell research.

Join the Conversation

Do you prioritize plant-based proteins or low-fat options in your diet? We want to hear your experience with healthy aging!

Leave a comment below or subscribe to our newsletter for the latest longevity breakthroughs.

0 comments
0 FacebookTwitterPinterestEmail
Health

AI tool estimates biological age from photos to predict cancer outcomes

by Chief Editor
written by Chief Editor

The Future of Precision Medicine: How AI Facial Analysis is Redefining Biological Age

For decades, clinicians have relied on chronological age—the number of candles on a birthday cake—to assess patient risk and predict survival outcomes. But the medical community is realizing that the calendar is a blunt instrument. Two people can both be 60 years classic, yet one may possess the physiological resilience of a 50-year-old, while the other faces the biological frailty of a 70-year-old.

Enter FaceAge, a deep learning AI tool developed by researchers at Mass General Brigham. By analyzing facial photographs, this technology is shifting the paradigm from “how old are you?” to “how fast are you aging?” This transition marks the beginning of a new era in non-invasive biomarkers.

Did you know? Research indicates that patients with cancer often appear biologically older than their actual age. On average, these patients appeared about five years older than their chronological age according to FaceAge assessments.

From Static Snapshots to Dynamic Tracking: The Rise of FAR

While a single photo can provide a “snapshot” of biological age—known as FaceAge Deviation (FAD)—the real breakthrough lies in longitudinal tracking. A recent study published in Nature Communications introduced the Face Aging Rate (FAR), which measures the change in biological age over time.

From Instagram — related to Face Aging Rate, From Static Snapshots

The difference is critical. FAD tells us where a patient stands today, but FAR tells us the trajectory of their health. In a study of 2,279 cancer patients, researchers found that median FAR results indicated facial aging outpaced chronological aging by 40%.

The implications for the future are profound. Rather than relying on a one-time assessment, doctors can now potentially track a patient’s biological decline or stability in near real-time. The data suggests that higher FAR—or accelerated biological aging—is significantly associated with decreased survival probability, particularly when the interval between photos is two years or more.

Why Dynamic Data Beats Static Readings

The research highlights that FAR is more likely to predict survival outcomes stably over longer intervals than a single-point FAD reading. By integrating both—starting with a baseline deviation and tracking the rate of change—clinicians can gain a nuanced view of a patient’s evolving health status.

Revolutionizing Oncology and Personalized Care

The integration of AI facial analysis into routine clinical workflows could fundamentally change how cancer is managed. Currently, treatment intensity is often based on a mix of tumor stage and chronological age. However, biological age provides a more accurate reflection of a patient’s ability to tolerate aggressive therapies.

Raymond Mak, MD, a radiation oncologist at Mass General Brigham Cancer Institute, notes that deriving a Face Aging Rate from routine photographs allows for “near real-time tracking of an individual’s health.” He suggests this could refine personalized treatment planning, improve how patients are counseled, and guide the frequency and intensity of oncology follow-ups.

Revolutionizing Oncology and Personalized Care
Pro Tip The Horizon Health Monitoring While
Pro Tip: When discussing prognosis with healthcare providers, ask about “biological markers” rather than just “age-based risks.” Understanding the difference between chronological and biological age can lead to more tailored conversations about treatment tolerance.

The scale of this potential is evident in a study published in JNCI: Journal of the National Cancer Institute, which tested FaceAge on more than 24,500 cancer patients over age 60. The results were striking: 65% of these patients had a FaceAge older than their chronological age. Those whose biological age was 10 or more years older than their actual age faced significantly worse survival outcomes.

Beyond Cancer: The Horizon of AI Health Monitoring

While the current focus is on oncology, the trajectory of FaceAge points toward a much broader application. If a simple selfie can predict outcomes for radiation therapy, it could theoretically be applied to any chronic disease that manifests physiological stress on the body.

Hugo Aerts, PhD, director of the AIM program at Mass General Brigham, envisions a future where this technology informs the health of individuals with various chronic diseases and even healthy populations. The goal is to create a cost-effective, non-invasive biomarker that empowers individuals to understand their own health trajectories.

As we move forward, People can expect to see these AI tools integrated into telehealth platforms and wearable tech, allowing for continuous, passive monitoring of biological aging as a proxy for overall systemic health. This could lead to earlier interventions for age-related decline before clinical symptoms even appear.

Comparison: Chronological vs. Biological Monitoring

  • Chronological Age: Static, universal, does not account for lifestyle or disease impact.
  • Biological Age (FAD): Reflects current physiological state; identifies “accelerated aging” at a single point in time.
  • Face Aging Rate (FAR): Dynamic, tracks the speed of aging; predicts survival and treatment response over time.

Frequently Asked Questions

What exactly is FaceAge?

FaceAge is a deep learning AI tool that analyzes facial photographs to estimate a person’s biological age, which reflects their physiological condition rather than the number of years they have lived.

FaceAge: Artificial Intelligence (AI) Tool Uses Face Photos to Reveal Biological Age

How does the Face Aging Rate (FAR) differ from a regular age estimate?

While a regular estimate tells you your biological age at one moment, FAR measures how that biological age changes over time. It’s calculated by taking the change in FaceAge and dividing it by the time elapsed between two photographs.

Can a photo really predict cancer survival?

While not a replacement for traditional diagnostics, research shows that accelerated biological aging (high FAR) and significant biological age deviation (high FAD) are associated with poorer survival probabilities in cancer patients receiving radiation therapy.

Is this technology available to the general public?

Yes, Mass General Brigham has launched an IRB-approved web portal at faceage.bwh.harvard.edu where the public can submit photographs for assessment and contribute to ongoing research.

What do you think about the use of AI to track your biological age? Would you trust a “selfie” to help guide your medical treatment? Let us know in the comments below or share this article with someone interested in the future of longevity and AI.

To stay updated on the latest breakthroughs in AI medicine and precision health, subscribe to our newsletter for weekly insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Oral bacteria can reveal your true biological age and health risks

by Chief Editor
written by Chief Editor

Beyond the Calendar: The Rise of Biological Age Tracking

For decades, we have relied on chronological age—the number of birthdays we’ve celebrated—to estimate our health risks. However, medical science is shifting toward “biological age,” a more accurate reflection of how our bodies are actually aging on a cellular and systemic level.

While gut-based aging clocks have paved the way, a new frontier is emerging in the oral cavity. Recent research published in Nature Communications suggests that the bacteria living in our mouths can serve as a powerful, non-invasive biomarker for systemic health and longevity.

Did you grasp? Researchers identified 64 specific age-dependent bacterial genera that can be used to predict a person’s chronological age and, more importantly, their biological aging acceleration.

Why Your Mouth is a Window to Systemic Health

The oral microbiome is not an isolated ecosystem; It’s deeply connected to the rest of the body. By analyzing oral rinse samples, scientists can now derive the Oral Microbiome Aging Acceleration (OMAA) Score. This score measures the residual difference between a person’s predicted microbiome age and their actual chronological age.

From Instagram — related to Score, Health

The implications of the OMAA Score are significant. Data shows that each unit of increase in this score is associated with approximately a 5% higher risk of both all-cause mortality and frailty. This suggests that the oral microbiome reflects an intrinsic, systemic aging process rather than just local oral hygiene.

Key Bacterial Markers to Watch

Certain taxa are now being linked to specific health outcomes, providing a roadmap for future diagnostic tools:

  • Rothia: Closely correlated with increased frailty.
  • Scardovia: Potentially reflects changes in carbohydrate metabolism.
  • Filifactor: Associated with periodontal inflammation.

Interestingly, these patterns persist even in individuals without overt periodontal disease, indicating a general shift toward low-grade dysregulation as we age.

The Future of Non-Invasive Health Screening

The transition from laboratory-based 16S rRNA sequencing to point-of-care testing could revolutionize preventive medicine. Because oral samples are easily collected during routine screenings, this method is far more scalable than gut microbiome analysis.

Your Mouth’s Microbiome May Reveal Your True Biological Age

We are moving toward a future where a simple oral rinse could be part of an annual check-up, flagging high-risk individuals long before clinical symptoms appear. This is particularly vital for identifying early risks of kidney decline, as the OMAA Score has already shown a correlation with impaired kidney function (lower eGFR).

Pro Tip: While the OMAA Score is primarily driven by intrinsic aging, maintaining oral health remains a cornerstone of systemic wellness. Look for screening tools that prioritize non-invasive, scalable biomarkers for a holistic view of your health.

From Data to Prevention: Predicting Chronic Disease

One of the most promising trends is the integration of microbiome data with conventional risk factors. The OMAA Score has already demonstrated an ability to enhance the prediction of life-threatening events:

  • Cancer Risk: Improved predictive power (AUC 0.70 vs. 0.67).
  • Heart Attack Risk: Enhanced accuracy (AUC 0.79 vs. 0.76).

advanced machine learning models, such as Transformer-based Robust Principal Component Analysis (TRPCA), are improving the accuracy of age prediction across multiple body sites, including the skin, gut, and mouth. This multi-site approach could eventually lead to a “universal biological clock” that provides a comprehensive snapshot of human aging.

For those interested in how these biomarkers interact with other systems, exploring the basics of the microbiome can provide essential context on how microbial communities influence host health.

Frequently Asked Questions

What is the OMAA Score?

The Oral Microbiome Aging Acceleration (OMAA) Score is a metric derived from machine learning analysis of oral bacteria. It compares your predicted microbiome age to your actual chronological age to determine if you are aging faster or slower than expected.

Frequently Asked Questions
Score Health Oral

Can diet or medication change my biological age score?

Research indicates that diet has a limited impact on the OMAA Score. While some medications (such as antiplatelet drugs like clopidogrel) show a weak association with increased aging, these are likely linked to the patient’s underlying health status rather than the medication itself.

Is this test available for the general public?

Currently, these findings rely on laboratory-based 16S rRNA sequencing. While not yet a common point-of-care test, the study supports the potential for these screenings to be used in low-resource settings in the future.

What does a high OMAA score indicate?

A higher OMAA score is associated with an increased risk of frailty, all-cause mortality, and impaired kidney function, and it can improve the prediction of cancer and heart attack risks.

Want to stay ahead of the curve in longevity science? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on biological aging and preventive health.

0 comments
0 FacebookTwitterPinterestEmail
Health

High-fat, low-carbohydrate diet may improve beta-cell function in patients with type 2 diabetes

by Chief Editor
written by Chief Editor

The Shift Toward Beta-Cell Recovery in Type 2 Diabetes

For years, the approach to managing type 2 diabetes has focused primarily on controlling blood sugar levels through medication and weight loss. However, emerging research suggests a pivot toward a more fundamental goal: recovering the function of the pancreas’s beta-cells.

Beta-cells are the endocrine cells responsible for producing and releasing insulin. In type 2 diabetes, these cells often suffer from insufficiency or failure, a process compounded by insulin resistance. While medication can manage the symptoms, lead researcher Barbara Gower, Ph.D., notes that recovering these beta-cells is an outcome that cannot be achieved with medication alone.

Did you know? Beta-cell failure is a primary driver in the development and progression of type 2 diabetes, often exacerbated by the consumption of too many carbohydrates.

The Role of Ketogenic Diets in Organ Stress

Recent data published in the Journal of the Endocrine Society highlights the potential of a ketogenic diet—a high-fat, low-carbohydrate eating plan—to reduce stress on the pancreas. Unlike traditional low-fat diets, a ketogenic approach shifts hepatic metabolism to favor burning fat over storing it.

From Instagram — related to Beta, Toward

A study involving 51 participants (71% female, aged 55-62) found that three months of a ketogenic diet improved beta-cell function. This improvement was linked to a decrease in the proinsulin-C-peptide ratio, which serves as a critical biomarker for pancreas stress.

Interestingly, these benefits were observed even without substantial weight loss. While both the ketogenic and low-fat groups in the study lost a modest amount of weight, the ketogenic group saw a significantly greater reduction in the proportion of proinsulin secreted.

Moving Toward Medication Deprescribing

One of the most significant trends in diabetes management is the potential for “deprescribing.” As beta-cell function improves, some adults with type 2 diabetes may find they can better manage their disease and potentially discontinue certain medications.

This transition is not something to be done in isolation. Experts emphasize that the effective use of low-carbohydrate (LC) diets requires:

  • Close and intensive lifestyle counseling.
  • A safe, supervised approach to medication management.
  • Consistent monitoring of blood glucose and insulin responses.

For those with mild type 2 diabetes, reducing carbohydrate intake allows for a diet higher in protein that meets energy needs while reducing the burden on the pancreas. You can learn more about carbohydrate restriction in T2D through the Endocrine Society.

Pro Tip: If you are considering a low-carb or ketogenic transition, always consult your healthcare provider first. Because these diets can improve insulin sensitivity, medication dosages may need to be adjusted quickly to prevent hypoglycemia.

Understanding the Biomarkers of Success

The future of diabetes care is moving toward precision medicine, using biomarkers to track internal organ health rather than just surface-level blood sugar numbers. The proinsulin-C-peptide ratio is a key example of this shift.

How a Plant-Based Diet Improves Beta-Cell Function (Pancreas) | Mastering Diabetes | Dr Neal Barnard

A high ratio indicates that the beta-cells are under stress and struggling to process insulin correctly. By tracking the reduction of this ratio, clinicians can see a direct correlation between dietary changes and the actual recovery of pancreatic function, providing a more accurate picture of “diabetes reversal” than weight loss alone.

For further reading on how these patterns impact health, explore our guide on personalized nutrition for metabolic health.

Frequently Asked Questions

What is a ketogenic diet?

A ketogenic diet is a high-fat, low-carbohydrate eating plan designed to shift the body’s metabolism to burn fat for energy instead of glucose.

Frequently Asked Questions
Beta Toward

Can a low-carb diet actually “fix” beta-cells?

Research suggests that a ketogenic diet may reduce stress on the pancreas and improve the ability of beta-cells to secrete insulin, an outcome that medication typically cannot achieve.

Is weight loss necessary to see these benefits?

While weight loss is often associated with diabetes improvement, studies have shown that improvements in beta-cell function and the proinsulin-C-peptide ratio can occur without substantial weight loss.

Is it safe to stop diabetes medication on a low-carb diet?

Only under strict medical supervision. Safe medication management and deprescribing require intensive lifestyle counseling and professional oversight to ensure safety.

Join the Conversation: Have you explored low-carbohydrate patterns for your health? Share your experience in the comments below or subscribe to our newsletter for the latest updates on metabolic research!

0 comments
0 FacebookTwitterPinterestEmail
Health

Older adults show high willingness for Alzheimer’s blood tests

by Chief Editor
written by Chief Editor

Alzheimer’s Blood Tests: A New Era of Early Detection and Patient Empowerment

For decades, the fear of Alzheimer’s disease has loomed large, often accompanied by uncertainty and delayed diagnoses. Now, a groundbreaking shift is underway, driven by the development of blood-based biomarker tests and a surprising willingness among patients to embrace them. A recent Northwestern Medicine survey reveals that over 85% of individuals would agree to undergo such a test if recommended by their doctor, signaling a potential revolution in how we approach this devastating disease.

The Anxiety Behind the Symptoms

Northwestern University psychologist Andrea Russell, who works directly with patients experiencing early cognitive changes, has witnessed firsthand the anxiety surrounding potential Alzheimer’s. Many patients worry over missed words, forgotten appointments, or fear making mistakes in public. This fear, coupled with the stigma associated with dementia, often prevents individuals from seeking timely medical evaluation.

The Anxiety Behind the Symptoms
Alzheimer Blood Early

From Invasive Procedures to a Simple Blood Draw

Traditionally, diagnosing Alzheimer’s involved costly and invasive procedures like PET scans and spinal taps, limiting access for many, particularly those in primary care settings. Blood-based biomarker tests offer a less invasive, more affordable alternative, detecting abnormal levels of amyloid and tau proteins associated with the disease. Although a couple of these tests received FDA clearance last year for individuals already exhibiting symptoms, their broader application is on the horizon.

What the Survey Revealed: Patient Perspectives

The Northwestern Medicine survey, encompassing nearly 600 primary care patients with an average age of 62, uncovered compelling insights. Before receiving information about the tests, 84% of respondents were unaware of their existence. However, after a brief explanation, 85% expressed willingness to undergo testing if recommended by their clinician. A significant 94% believed offering these tests to patients with memory or thinking problems was important.

Motivations for accepting the test centered around informed medical care (94%), insurance coverage (93%), comprehensive education (88%), and convenience (88%). Concerns revolved around cost (49%), test reliability (35%), fear of a positive result (22%), and potential differential treatment (24%).

Beyond Diagnosis: Empowering Proactive Brain Health

Interestingly, nearly three-quarters of participants anticipated emotional distress following a positive result, yet a remarkable 87% indicated they would likely grab steps to improve their brain health. This highlights a crucial point: even in the face of a potentially frightening diagnosis, individuals are motivated to take proactive measures.

Act For Older Adults

“What’s healthy for the brain is healthy for the body,” explains Russell. “If people learn they may be at higher risk, they may want to take action, such as managing chronic conditions, improving nutrition and staying engaged with their medical care. Those steps could help them prolong independence and well-being.”

The “New Cancer Diagnosis” and the Necessitate for Early Intervention

Russell describes Alzheimer’s as “the new cancer diagnosis” for many patients, noting their dissatisfaction with diagnostic delays, and uncertainty. Early detection isn’t just about confirming a diagnosis; it’s about empowering patients to plan ahead, access resources, and participate in clinical trials as researchers strive for better treatments. It similarly allows providers to intervene earlier, potentially slowing disease progression.

From Instagram — related to Alzheimer, Blood

Limitations and Future Directions

While promising, these blood tests aren’t without limitations. Results aren’t always conclusive, and a positive result doesn’t guarantee the development of dementia. Researchers are actively refining these biomarkers and exploring optimal implementation strategies within primary care settings. The tests measure proteins linked to amyloid plaques, and clinical trials have shown these tests closely match results from current gold standards.

Frequently Asked Questions

  • What do these blood tests measure? They measure proteins linked to amyloid plaques in the brain, a hallmark of Alzheimer’s disease.
  • Are the tests widely available now? While a few have received FDA clearance, they are not yet in widespread use.
  • Will a positive test result mean I definitely have Alzheimer’s? No, a positive result indicates an increased risk but doesn’t confirm a diagnosis.
  • What can I do if I’m concerned about Alzheimer’s? Talk to your doctor about your concerns and discuss whether a blood test or other evaluation is appropriate.

Pro Tip: Maintaining a healthy lifestyle – including regular exercise, a balanced diet, and social engagement – is crucial for brain health, regardless of your risk factors.

Did you know? Alzheimer’s disease is projected to nearly double by 2060, affecting an estimated 14.4 million older adults in the U.S.

Want to learn more about Alzheimer’s disease and the latest research? Visit the Alzheimer’s Association website for valuable resources and support.

0 comments
0 FacebookTwitterPinterestEmail
Health

New biomarker predicts prognosis and treatment response in colorectal cancer

by Chief Editor
written by Chief Editor

New Biomarker Offers Hope for Personalized Colorectal Cancer Treatment

A newly identified protein, CTHRC1, found in cells within the tumor microenvironment, is showing promise as a biomarker to predict immunotherapy response and overall prognosis for patients with colon and rectal cancer. Research published in Gut, led by a team from the Hospital del Mar Research Institute (HMRIB), the Institute for Research in Biomedicine (IRB Barcelona) and CIBER Oncology (CIBERONC), suggests this discovery could significantly refine treatment strategies.

Understanding Cancer-Associated Fibroblasts and CTHRC1

The study focuses on cancer-associated fibroblasts (CAFs) – connective tissue cells that support tumor growth. Specifically, researchers identified a subset of these cells, CTHRC1(+) CAFs, expressing the CTHRC1 protein. These cells appear to play a crucial role in tumor proliferation and, importantly, can be detected using standard immunohistochemistry tests already available in most hospital pathology labs.

Predicting Immunotherapy Success

Currently, immunotherapy is only effective in approximately 5% of colon and rectal cancer patients. This new biomarker could dramatically improve patient selection for this treatment. The presence of CTHRC1(+) CAFs appears to indicate the state of immune cells within the tumor and their capacity to fight cancer cells. This means patients previously considered ineligible for immunotherapy might now be viable candidates.

Predicting Immunotherapy Success

Dr. Clara Montagut, Head of Section of the Medical Oncology Department at Hospital del Mar, explains that this biomarker “could help guide therapeutic strategies for patients with colon and rectal cancer.”

Beyond Immunotherapy: Prognosis and Potential Drug Targets

The implications extend beyond immunotherapy. High levels of the CTHRC1 protein are linked to treatment resistance and poorer disease outcomes, as it measures the activity of TGF-beta, a cytokine in the tumor microenvironment. This suggests that inhibiting CTHRC1 could be a potential therapeutic approach. Researchers are now exploring inhibitors of this protein as a future treatment option.

Large-Scale Validation and International Collaboration

The findings have been rigorously validated across 17 cohorts, encompassing data from nearly 3,000 patients, and utilizing samples from hospitals in Valencia, Barcelona, and Hospital del Mar. Dr. Alexandre Calon, coordinator of the Translational Research Group in tumor Microenvironment at HMRIB, emphasizes the “strong predictive and prognostic performance across patient cohorts.”

Potential Applications to Other Cancers

While the initial research focuses on colorectal cancer, the team believes the findings could be applicable to other tumor types, including breast and lung cancer. Further research is needed to confirm these possibilities.

Future Trends in Colorectal Cancer Biomarkers

The identification of CTHRC1(+) CAFs represents a significant step towards personalized medicine in colorectal cancer. Looking ahead, several trends are likely to shape the future of biomarker research in this field:

  • Single-Cell Analysis: The study’s use of single-cell RNA analysis is likely to become more widespread, allowing for a more detailed understanding of the complex interactions within the tumor microenvironment.
  • Artificial Intelligence (AI): AI and machine learning algorithms are increasingly being used to analyze large datasets of patient data and identify novel biomarkers. Recent advancements suggest AI can predict treatment response in colorectal cancer patients.
  • Liquid Biopsies: The development of liquid biopsies – analyzing circulating tumor cells or DNA in the bloodstream – offers a non-invasive way to monitor treatment response and detect recurrence.
  • Multi-Biomarker Panels: Rather than relying on a single biomarker, future diagnostic tools are likely to incorporate panels of biomarkers to provide a more comprehensive assessment of a patient’s disease.

Did you know?

Immunotherapy has shown remarkable success in treating certain cancers, but its effectiveness varies significantly depending on the individual and the type of cancer. Identifying biomarkers like CTHRC1 is crucial for maximizing the benefits of this treatment.

Frequently Asked Questions

  • What is a biomarker? A biomarker is a measurable substance or characteristic that indicates the presence or severity of a disease.
  • What are cancer-associated fibroblasts? These are cells within the tumor microenvironment that support tumor growth and can influence treatment response.
  • How is CTHRC1 detected? CTHRC1 can be detected using immunohistochemistry, a routine test performed in hospital pathology labs.
  • Will this biomarker be available to all patients soon? The researchers are working to integrate this marker into routine clinical practice, but widespread availability will take time and further validation.

This research offers a beacon of hope for more effective and personalized treatment strategies for colorectal cancer. By refining patient selection for immunotherapy and identifying potential new drug targets, the discovery of CTHRC1(+) CAFs could significantly improve outcomes for those battling this disease.

Desire to learn more about colorectal cancer research? Explore our other articles on the latest advancements in cancer treatment and prevention.

0 comments
0 FacebookTwitterPinterestEmail
Health

Study finds long COVID leaves a distinct immune signature in the blood

by Chief Editor
written by Chief Editor

Unlocking Long COVID: New Protein Patterns Offer Hope for Diagnosis and Treatment

Recent research is shedding light on the complex biological mechanisms behind Long COVID, identifying distinct protein patterns in the blood that differentiate those still struggling with symptoms months after infection from those who have recovered. A study published in Communications Medicine reveals key inflammatory and neurological markers, offering potential avenues for improved diagnosis and targeted therapies.

The Persistent Puzzle of Long COVID

An estimated 5% to 30% of individuals infected with SARS-CoV-2 experience symptoms lasting months, a condition known as Long COVID. The core question remains: why do some fully recover while others face debilitating fatigue, brain fog, and chronic inflammation? Researchers are increasingly focused on immune dysregulation as a key factor, but identifying reliable biomarkers has proven challenging.

Key Protein Signatures Identified

The study, conducted on participants in Australia, compared blood samples from healthy individuals, those who had recovered from COVID-19, and individuals experiencing Long COVID. Researchers measured 182 inflammatory and neurology-related proteins, pinpointing several that stood out. Elevated levels of interleukin-20 (IL-20), macrophage chemoattractant protein-1 (MCP-1), and neuroblastoma suppressor of tumorigenicity 1 (NBL1) were particularly prominent in individuals with Long COVID, suggesting ongoing inflammation.

Interestingly, even those who had recovered from the initial infection showed some lingering protein differences compared to healthy controls, with fibroblast growth factor 19 (FGF-19) and cystatin D (CST5) associated with recovery status. This suggests that immune alterations can persist even after clinical recovery.

Pro Tip: Understanding these protein signatures could lead to the development of diagnostic tests to identify individuals at risk of developing Long COVID early on, allowing for proactive intervention.

Vaccination and Reinfection: A Shifting Immune Landscape

The research also investigated how vaccination and reinfection impact these protein patterns. Booster doses prompted strong antibody responses in all groups, but individuals with Long COVID and those who had previously recovered exhibited lower spike-specific antibody levels after breakthrough infections compared to those newly infected.

Crucially, the study found that the inflammatory patterns observed after the initial infection were not replicated following reinfection in individuals with Long COVID. This suggests the immune system reacts differently upon subsequent exposure to the virus.

Perhaps most reassuringly, vaccination did not worsen inflammation in individuals with Long COVID. in fact, inflammatory protein levels either stabilized or decreased. This reinforces the importance of vaccination, even for those experiencing long-term symptoms.

Implications for Future Research and Treatment

These findings represent a significant step forward in unraveling the complexities of Long COVID. Identifying these distinct immune alterations opens doors for developing targeted therapies aimed at modulating the immune response and alleviating symptoms. Further research is needed to validate these findings in larger cohorts and explore the potential of these protein markers as diagnostic tools.

The Role of Persistent Viral Presence

Emerging research suggests that the persistence of SARS-CoV-2 RNA or particles in tissues may play a role in driving the chronic inflammation seen in Long COVID. While the exact mechanisms are still being investigated, this persistent viral presence could be triggering ongoing immune dysregulation.

FAQ: Long COVID and Immune Response

Q: What is Long COVID?
A: Long COVID refers to symptoms that persist for weeks or months after the initial SARS-CoV-2 infection.

Q: Are vaccinations safe for people with Long COVID?
A: This study suggests vaccinations are well-tolerated and do not worsen inflammation in individuals with Long COVID.

Q: What are the key symptoms of Long COVID?
A: Common symptoms include fatigue, brain fog, and chronic inflammation.

Q: Can reinfection with SARS-CoV-2 worsen Long COVID?
A: The immune response to reinfection appears different than the initial infection, but this study did not find evidence of worsened inflammation.

Did you know? The number of symptoms associated with Long COVID exceeds 200, highlighting the diverse and individualized nature of the condition.

Wish to learn more about the latest research on Long COVID? Visit the CDC’s Long COVID page for up-to-date information and resources.

Share your experiences with Long COVID in the comments below. What symptoms have you experienced, and how has vaccination impacted your recovery?

0 comments
0 FacebookTwitterPinterestEmail
Health

Sylvester Comprehensive Cancer Center opens new trial for neuroendocrine tumors

by Chief Editor
written by Chief Editor

Hope on the Horizon: New Trial Targets Aggressive Neuroendocrine Tumors

A new clinical trial at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is offering a beacon of hope for patients battling high-grade neuroendocrine tumors (NETs). These complex and aggressive cancers have historically seen limited medical advancements due to their rarity and the resulting lack of research investment. For many, conventional chemotherapy has been the primary, and often insufficient, option.

Combining Immunotherapy and Oncolytic Virus Therapy

Led by Dr. Aman Chauhan, leader of the Neuroendocrine Tumor Program at Sylvester, the trial takes a novel approach. Patients will receive a combination of immunotherapy drugs – checkpoint inhibitors – and an oncolytic virus, Seneca Valley Virus-001 (SVV-001), injected directly into the tumors. This strategy aims to harness the power of the immune system to fight these challenging cancers.

Understanding the Challenge: “Cold” vs. “Hot” Tumors

Checkpoint inhibitors have shown promise in treating various cancers, including melanoma and lung cancer. But, very few high-grade neuroendocrine carcinomas respond to these drugs. When they do, the responses can be long-lasting. The key challenge lies in increasing the number of patients who experience a full response.

Understanding the Challenge: "Cold" vs. "Hot" Tumors

SVV-001 is designed to address this. Unlike traditional therapies, SVV-001 selectively infects and destroys tumor cells, releasing their contents and activating the immune system. This process can transform “cold” tumors – those that don’t attract immune attention – into “hot” tumors, making them more susceptible to immunotherapy. Dr. Chauhan’s previous preclinical studies demonstrated that this combination shrank tumors and yielded durable responses.

Targeting TEM8: A Biomarker for Enhanced Viral Delivery

The phase 1 trial will enroll approximately 36 patients whose tumors have become resistant to or have failed previous treatments. Researchers will also analyze patient tumors for the presence of TEM8, a newly identified biomarker. TEM8 binds to SVV-001, facilitating the virus’s attachment to and infection of cancer cells, effectively making SVV-001 a targeted immunotherapy.

A Growing Center for NET Expertise

Sylvester Comprehensive Cancer Center has rapidly become a leading destination for NET patients. In the past two years, over 550 new patients from 30 states and 10 countries have sought treatment and access to clinical trials at the center. Dr. Chauhan’s dedication to NET research is underscored by this new investigator-initiated trial focused specifically on high-grade neuroendocrine disease.

Remembering Sean Stone and Nichole Borchard

The urgency to locate better treatments is fueled by the devastating impact of these cancers. The loss of Sean Stone, a young Hollywood producer, at age 26, and Nichole Borchard, a mother of two who died at 39, highlights the aggressive nature of high-grade NETs. Their families have established foundations – Sean Stone’s Neuroendocrine Carcinoma Fundraiser and the Nichole Borchard Foundation – to support research and honor their legacies.

Future Trends in Neuroendocrine Tumor Treatment

The trial at Sylvester represents a significant step towards personalized medicine in NET treatment. The focus on biomarkers like TEM8 and the combination of immunotherapy with oncolytic viruses are indicative of broader trends in cancer research.

Increased Focus on Immunotherapy Combinations

Expect to see more trials exploring combinations of different immunotherapies, as well as immunotherapy paired with targeted therapies and other novel agents. The goal is to overcome resistance and broaden the reach of immunotherapy to more patients.

The Rise of Oncolytic Viruses

Oncolytic viruses, like SVV-001, are gaining traction as a promising cancer treatment modality. Their ability to selectively kill cancer cells and stimulate an immune response makes them an attractive option, particularly in combination with other therapies.

Precision Medicine Guided by Biomarkers

Identifying biomarkers that predict treatment response will be crucial for tailoring therapies to individual patients. The discovery of TEM8 is a prime example of how biomarker research can improve treatment outcomes.

Frequently Asked Questions

What are neuroendocrine tumors? Neuroendocrine tumors originate from cells found throughout the body and can affect most organ systems.

What is immunotherapy? Immunotherapy uses the body’s own immune system to fight cancer.

What is an oncolytic virus? An oncolytic virus is a virus that selectively infects and destroys cancer cells.

Where can I learn more about clinical trials at Sylvester? Visit the Sylvester Comprehensive Cancer Center website or contact their clinical trial team.

Did you recognize? Approximately one-sixth of neuroendocrine tumors are classified as high grade, and survival rates are often poor.

Pro Tip: Early detection is crucial for improving outcomes in neuroendocrine tumors. If you experience persistent symptoms, consult with a healthcare professional.

Stay informed about the latest advancements in neuroendocrine tumor treatment. Explore more articles on our website and subscribe to our newsletter for updates.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts